Review
Open access
Sep 2026
Architects of Aggression: The Molecular Blueprint of Glioma Progression
Despite decades of clinical validation, glioblastoma (GBM) treatment remains tethered to a dismal 15-to-16-month survival plateau, heavily thwarted by the ys blood–brain barrier (BBB) and profound cellular heterogeneity. While the 2021 World Health Organization Classification of Tumors of the Central Nervous System (WH...
D. Aebisher, Jakub Tylutki, Angelika Myśliwiec et al.
· Genes · 0 citations